Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16858303 | 0.79 | — | — | |
| SCHEMBL14097301 | 0.77 | NLRP3 (0.33) | GRIA1 | |
| SCHEMBL6969058 | 0.75 | LMNA (0.36) | GRIA1 | |
| SCHEMBL25589839 | 0.75 | GRIA1 (0.34) | GRIA1 | |
| SCHEMBL6494923 | 0.75 | CA1 (0.31) | GRIA1 | |
| SCHEMBL20076074 | 0.75 | TSHR (0.36) | — | |
| SCHEMBL28911775 | 0.73 | BBOX1 (0.46) | — | |
| SCHEMBL24259785 | 0.73 | KMT2A (0.37) | — | |
| SCHEMBL26724609 | 0.73 | CA1 (0.44) | GRIA1 | |
| SCHEMBL7049896 | 0.73 | CA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-06-04 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | SLC6A2 61/4885SLC6A4 204/4885SLC6A3 130/4885 |
| US-11078189-B2 | Pharmaceutical compounds | HRH4, CHRM5, CHRM1 | SLC6A2 1482/4885SLC6A4 2486/4885SLC6A3 2412/4885 |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | HRH4, CHRM5, CHRM1 | SLC6A2 1482/4885SLC6A4 2486/4885SLC6A3 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.